LaVoieHealthScience (LHS), an integrated investor and public relations agency focused on advancing health and science innovations, today announced that it has added Emmaus Life Sciences, Inc. to its client roster.
LHS provides strategic communications programming to Emmaus, helping to ensure all stakeholders—including patients, healthcare practitioners, investors, and other audiences—are educated and aware of sickle cell disease and Emmaus’ dedication to patients with this orphan disease.
Emmaus has a history rooted in scientific discovery. Endari™ (L-glutamine oral powder), approved in July 2017, was developed by Emmaus’ Chairman and CEO Yutaka Niihara, M.D., MPH. Dr. Niihara began researching the benefits of L-glutamine more than 25 years ago in 1992, as a physician treating sickle cell patients at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. Today, the company’s product pipeline includes the potential use of L-glutamine to treat diverticulosis, a GI condition affecting millions, as well as diabetes. In addition, Emmaus is researching cell-sheet technology for treatment of limbal stem-cell deficiency, an orphan disease.
“We understand the importance of extending our visibility and building patient awareness of the treatment options for this debilitating orphan disease,” commented Kurt Kruger, CFO of Emmaus Life Sciences. “LHS, with its focus and expertise in the health and life science industry and connections with influencers, investment community and media make it the right partner for Emmaus.”
“We are honored to be working with Emmaus, a company led by Dr. Niihara that is truly passionate about patients and committed to medical innovation,” said Donna L. LaVoie, President & CEO of LaVoieHealthScience. “We are aligned with Emmaus’ passion to help patients afflicted with sickle cell disease and to raise the visibility of this disease, and the company’s important contributions to this underserved patient community.”
